Select therapeutic use:

Aesthetic medicine:

Indications for XEOMIN:

Temporary improvement in the appearance of moderate-to-severe glabellar lines associated with corrugator and/or procerus muscle activity.

Adult:

Should be administered and managed by experienced physicians. Max cumulative dose: 400 Units in a treatment session. ≥18yrs: Initial total dose: 20 Units per treatment session divided into 5 equal injections of 4 Units each (2 injections in each corrugator muscle and 1 injection in the procerus muscle). May repeat treatments no sooner than every 12 weeks.

Children:

<18yrs: not established.

Contraindications:

Infection at proposed injection site.

Boxed Warning:

Distant spread of toxin effect.

Warnings/Precautions:

Not interchangeable with other botulinum toxin products. Risk of distant spread of toxin effect (esp. in children treated for spasticity); see full labeling. Pre-existing dysphagia or breathing difficulties. Patients with smaller neck muscle mass or those who require bilateral inj into the sternocleidomastoid muscles: increased risk of dysphagia. Neuromuscular disorders (eg, myasthenia gravis, ALS, Lambert-Eaton syndrome); monitor closely. Compromised respiratory function; monitor. Narrow angle glaucoma. Contains human albumin; monitor for possible viral disease or Creutzfeldt-Jakob disease transmission. Elderly. Pregnancy. Nursing mothers.

Pharmacologic Class:

Neuromuscular blocker.

Interactions:

May be potentiated by aminoglycosides or other agents interfering with neuromuscular transmission (eg, tubocurarine-type muscle relaxants). May potentiate anticholinergic effects with concomitant anticholinergic drugs. Concomitant other botulinum toxin products or muscle relaxants may potentiate neuromuscular weakness.

Adverse Reactions:

Chronic sialorrhea: tooth extraction, dry mouth, diarrea, hypertension. Upper limb spasticity: seizure, nasopharyngitis, dry mouth, upper respiratory tract infection (RTI). Cervical dystonia: dysphagia (may be severe), neck pain, muscle weakness, inj site reactions, musculoskeletal pain. Blepharospasm: eyelid ptosis, dry eye, dry mouth, diarrhea, headache, visual impairment; corneal exposure/ulceration, ectropion (avoid inj into lower lid area). Glabellar lines: headache; ptosis. All: hypersensitivity reactions (discontinue if occur), possible antibody formation.

Generic Availability:

NO

How Supplied:

Single-use vial—1

Pricing for XEOMIN

100 units vial (Qty: 1)
Appx. price $486
GoodRx

Muscle spasms:

Indications for XEOMIN:

Chronic sialorrhea. Upper limb spasticity. Cervical dystonia. Blepharospasm.

Adult:

Should be administered and managed by experienced physicians. Max cumulative dose: 400 Units in a treatment session. ≥18yrs: Individualize; see full labeling. Chronic sialorrhea: inject 30 Units into each parotid gland and 20 Units into each submandibular gland (4 total inj sites); total dose: 100 Units per treatment session. Upper limb spasticity (not previously treated): initially give dose at the low end of dosing range and titrate as needed. Cervical dystonia: initial total dose: 120 Units per treatment session. Blepharospasm (treatment-naive): initial total dose: 50 Units (25 Units/eye); (previously-treated): consider dose, response, duration of effect, adverse reactions from previous botulinum toxin A treatment to determine dose. Max 100 Units per treatment session (50 Units/eye). For all: dose, number, and location of inj sites should be based on the size, number and location of muscles involved, severity, and response to any previous botulinum toxin inj. May repeat treatments no sooner than every 12 weeks (16 weeks for chronic sialorrhea).

Children:

<18yrs: not established.

Contraindications:

Infection at proposed injection site.

Boxed Warning:

Distant spread of toxin effect.

Warnings/Precautions:

Not interchangeable with other botulinum toxin products. Risk of distant spread of toxin effect (esp. in children treated for spasticity); see full labeling. Pre-existing dysphagia or breathing difficulties. Patients with smaller neck muscle mass or those who require bilateral inj into the sternocleidomastoid muscles: increased risk of dysphagia. Neuromuscular disorders (eg, myasthenia gravis, ALS, Lambert-Eaton syndrome); monitor closely. Compromised respiratory function; monitor. Narrow angle glaucoma. Contains human albumin; monitor for possible viral disease or Creutzfeldt-Jakob disease transmission. Elderly. Pregnancy. Nursing mothers.

Pharmacologic Class:

Neuromuscular blocker.

Interactions:

May be potentiated by aminoglycosides or other agents interfering with neuromuscular transmission (eg, tubocurarine-type muscle relaxants). May potentiate anticholinergic effects with concomitant anticholinergic drugs. Concomitant other botulinum toxin products or muscle relaxants may potentiate neuromuscular weakness.

Adverse Reactions:

Chronic sialorrhea: tooth extraction, dry mouth, diarrea, hypertension. Upper limb spasticity: seizure, nasopharyngitis, dry mouth, upper respiratory tract infection (RTI). Cervical dystonia: dysphagia (may be severe), neck pain, muscle weakness, inj site reactions, musculoskeletal pain. Blepharospasm: eyelid ptosis, dry eye, dry mouth, diarrhea, headache, visual impairment; corneal exposure/ulceration, ectropion (avoid inj into lower lid area). Glabellar lines: headache; ptosis. All: hypersensitivity reactions (discontinue if occur), possible antibody formation.

Generic Availability:

NO

How Supplied:

Single-use vial—1

Pricing for XEOMIN

100 units vial (Qty: 1)
Appx. price $486
GoodRx